Journal: Cancer Reports
Article Title: Decoding the Oncogenic Role of USP22 Through Pan‐Cancer Genomic and Epigenetic Analysis
doi: 10.1002/cnr2.70572
Figure Lengend Snippet: The expression of USP22 in various malignancies and the corresponding normal tissues was obtained using Timer 2.0. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B‐cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma. The number of stars represents the statistical significance as determined by the Wilcoxon test (** p < 0.01, and *** p < 0.001).
Article Snippet: The Human Protein Atlas, UALCAN, and Timer 2.0 were used to examine USP22 expression at the gene and protein levels in 33 TCGA cancer types.
Techniques: Expressing